{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:24:10Z","timestamp":1793381050015,"version":"4.5.0"},"reference-count":19,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T00:00:00Z","timestamp":1638230400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100010990","name":"Canadian Association of Pharmacy in Oncology","doi-asserted-by":"crossref","award":["2021RG001"],"award-info":[{"award-number":["2021RG001"]}],"id":[{"id":"10.13039\/100010990","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Immune-related adverse events are complications of immune checkpoint inhibitors which require robust patient education and proactive follow-up to ensure timely identification and management. Oncology pharmacist practice models with other anticancer modalities have been well documented, but there is limited evidence assessing the spectrum of pharmacist interventions in patients receiving immune checkpoint inhibitor(s) and the impact of these interventions on patient outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients initiated on immune checkpoint inhibitor(s) from 1 January 2016 to 31 August 2019 were included for data collection and analysis. Part 1 featured an intensive pharmacist follow-up cohort (study cohort) and summarized pharmacist interventions. Part 2 compared patient outcomes between the study cohort and a standard of care cohort (control cohort) from a different oncology centre. Patient outcomes included emergency department visits not resulting in admission, hospitalizations due to immune-related adverse event(s), immune checkpoint inhibitor cycles received, treatment discontinuation due to immune-related adverse event(s), completion of finite programmed death-1\/death-1 ligand treatment course and completion of ipilimumab. Clinical outcomes were compared using a retrospective, matched cohort design based on age, cancer diagnosis and immune checkpoint inhibitor(s).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 143 patients were included in Part 1 encompassing 1664 pharmacist recommendations across 11 categories. The matched cohort yielded 92 matches (n\u2009=\u2009184) with a higher odds of immune checkpoint inhibitor discontinuation due to immune-related adverse event(s) in the control cohort (odds ratio (OR) (95% confidence interval (CI))\u2009=\u20095.5 (1.2\u221224.8); p\u2009=\u20090.022).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Intensive immune-related adverse event education, proactive follow-up and immune-related adverse event management by pharmacists result in clinically meaningful interventions which correlate to improved patient outcomes, namely lower odds of treatment discontinuation due to immune-related adverse event(s).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552211061133","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T14:10:53Z","timestamp":1638281453000},"page":"145-154","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":18,"title":["Evaluation and clinical impact of a pharmacist-led, interdisciplinary service focusing on education, monitoring and toxicity management of immune checkpoint inhibitors"],"prefix":"10.1177","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5239-4350","authenticated-orcid":false,"given":"Glenn","family":"Myers","sequence":"first","affiliation":[{"name":"Horizon Health Network, The Moncton Hospital, Moncton, New Brunswick, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Stevens","sequence":"additional","affiliation":[{"name":"Horizon Health Network, Saint John Regional Hospital, Saint John, New Brunswick, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Flewelling","sequence":"additional","affiliation":[{"name":"Horizon Health Network, Saint John Regional Hospital, Saint John, New Brunswick, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Richard","sequence":"additional","affiliation":[{"name":"Dalhousie University, Halifax, Nova Scotia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meagan","family":"London","sequence":"additional","affiliation":[{"name":"Dalhousie University, Halifax, Nova Scotia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,11,30]]},"reference":[{"key":"bibr1-10781552211061133","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0300-z"},{"key":"bibr2-10781552211061133","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv623"},{"key":"bibr3-10781552211061133","unstructured":"Yervoy (ipilimumab) [product monograph]. Montreal, Quebec: Bristol-Myers Squibb Canada [online]. 2019, https:\/\/pdf.hres.ca\/dpd_pm\/00051965.PDF (accessed 3\u20138 September 2019)."},{"key":"bibr4-10781552211061133","unstructured":"Keytruda (pembrolizumab) [product monograph]. Kirkland, Quebec: Merck Canada Inc. [online]. 2019, https:\/\/pdf.hres.ca\/dpd_pm\/00052759.PDF (accessed 3\u20138 September 2019)."},{"key":"bibr5-10781552211061133","unstructured":"Opdivo (nivolumab) [product monograph]. Montreal, Quebec: Bristol-Myers Squibb Canada [online]. 2019, https:\/\/pdf.hres.ca\/dpd_pm\/00050129.PDF"},{"key":"bibr6-10781552211061133","unstructured":"Libtayo (cemiplimab) [product monograph]. Laval, Quebec: Sanofi-Aventis Canada Inc. [online]. 2019, https:\/\/pdf.hres.ca\/dpd_pm\/00050602.PDF"},{"key":"bibr7-10781552211061133","unstructured":"Tecentriq (atezolizumab) [product monograph]. Mississauga, Ontario: Hoffman-La Roche Limited [online]. 2019, https:\/\/pdf.hres.ca\/dpd_pm\/00052588.PDF"},{"key":"bibr8-10781552211061133","unstructured":"Imfinzi (durvalumab) [product monograph]. Mississauga, Ontario: AstraZeneca Canada Inc. [online]. 2019, https:\/\/pdf.hres.ca\/dpd_pm\/00052818.PDF"},{"key":"bibr9-10781552211061133","doi-asserted-by":"publisher","DOI":"10.3747\/co.27.5223"},{"key":"bibr10-10781552211061133","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481"},{"key":"bibr11-10781552211061133","doi-asserted-by":"publisher","DOI":"10.1177\/1078155215612541"},{"key":"bibr12-10781552211061133","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.000037"},{"key":"bibr13-10781552211061133","first-page":"171","volume":"11","author":"Sun C","year":"2018","journal-title":"J Pain Management"},{"key":"bibr14-10781552211061133","doi-asserted-by":"publisher","DOI":"10.1177\/1078155210389216"},{"key":"bibr15-10781552211061133","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219859424"},{"key":"bibr16-10781552211061133","doi-asserted-by":"publisher","DOI":"10.1177\/1078155218817937"},{"key":"bibr17-10781552211061133","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220928407"},{"key":"bibr18-10781552211061133","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.18.00319"},{"key":"bibr19-10781552211061133","volume-title":"Canadian Consensus on clinical pharmacy Key performance indicators: quick reference guide","author":"Fernandes O","year":"2015"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552211061133","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552211061133","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552211061133","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:25:46Z","timestamp":1777688746000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552211061133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,30]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1177\/10781552211061133"],"URL":"https:\/\/doi.org\/10.1177\/10781552211061133","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,30]]}}}